204 related articles for article (PubMed ID: 26205082)
1. A Neutralizing Antibody Assay Based on a Reporter of Antibody-Dependent Cell-Mediated Cytotoxicity.
Wu Y; Li JJ; Kim HJ; Liu X; Liu W; Akhgar A; Bowen MA; Spitz S; Jiang XR; Roskos LK; White WI
AAPS J; 2015 Nov; 17(6):1417-26. PubMed ID: 26205082
[TBL] [Abstract][Full Text] [Related]
2. Selection of a Ligand-Binding Neutralizing Antibody Assay for Benralizumab: Comparison with an Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Cell-Based Assay.
Wu Y; Akhgar A; Li JJ; Yu B; Chen C; Lee N; White WI; Roskos LK
AAPS J; 2018 Mar; 20(3):49. PubMed ID: 29541868
[TBL] [Abstract][Full Text] [Related]
3. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
[TBL] [Abstract][Full Text] [Related]
4. Development and validation of a cell-based SEAP reporter assay for the detection of neutralizing antibodies against an anti-IL-13 therapeutic antibody.
Liao K; Sikkema D; Wang C; Chen K; DeWall S; Lee TN
J Immunol Methods; 2012 Jan; 375(1-2):258-63. PubMed ID: 22001556
[TBL] [Abstract][Full Text] [Related]
5. An Antibody-Dependent Cellular Cytotoxicity Assay for Detecting Ocrelizumab Neutralizing Antibody.
Nguyen V; Cheung A; Hendricks R; Peng K; Chung S
AAPS J; 2023 Oct; 25(6):97. PubMed ID: 37783946
[TBL] [Abstract][Full Text] [Related]
6. GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab.
Gerdes CA; Nicolini VG; Herter S; van Puijenbroek E; Lang S; Roemmele M; Moessner E; Freytag O; Friess T; Ries CH; Bossenmaier B; Mueller HJ; Umaña P
Clin Cancer Res; 2013 Mar; 19(5):1126-38. PubMed ID: 23209031
[TBL] [Abstract][Full Text] [Related]
7. An IL-15 Superagonist, ALT-803, Enhances Antibody-Dependent Cell-Mediated Cytotoxicity Elicited by the Monoclonal Antibody NEO-201 Against Human Carcinoma Cells.
Fantini M; David JM; Wong HC; Annunziata CM; Arlen PM; Tsang KY
Cancer Biother Radiopharm; 2019 Apr; 34(3):147-159. PubMed ID: 30601063
[TBL] [Abstract][Full Text] [Related]
8. Development of a simple new flow cytometric antibody-dependent cellular cytotoxicity (ADCC) assay with excellent sensitivity.
Tanaka M; Ishige A; Yaguchi M; Matsumoto T; Shirouzu M; Yokoyama S; Ishikawa F; Kitabayashi I; Takemori T; Harada M
J Immunol Methods; 2019 Jan; 464():74-86. PubMed ID: 30389576
[TBL] [Abstract][Full Text] [Related]
9. A monoclonal antibody against hinge-cleaved IgG restores effector function to proteolytically-inactivated IgGs in vitro and in vivo.
Brezski RJ; Kinder M; Grugan KD; Soring KL; Carton J; Greenplate AR; Petley T; Capaldi D; Brosnan K; Emmell E; Watson S; Jordan RE
MAbs; 2014; 6(5):1265-73. PubMed ID: 25517311
[TBL] [Abstract][Full Text] [Related]
10. Engineering of Humanized Antibodies Against Human Interleukin 5 Receptor Alpha Subunit That Cause Potent Antibody-Dependent Cell-Mediated Cytotoxicity.
Kim JE; Lee DH; Jung K; Kim EJ; Choi Y; Park HS; Kim YS
Front Immunol; 2020; 11():593748. PubMed ID: 33488590
[TBL] [Abstract][Full Text] [Related]
11. Surrogate CD16-expressing effector cell lines for determining the bioactivity of therapeutic monoclonal antibodies.
Gurjar SA; Derrick JP; Dearman RJ; Thorpe R; Hufton S; Kimber I; Wadhwa M
J Pharm Biomed Anal; 2017 Sep; 143():188-198. PubMed ID: 28605680
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Rα, in Uncontrolled Eosinophilic Asthma.
Khorasanizadeh M; Eskian M; Assa'ad AH; Camargo CA; Rezaei N
Int Rev Immunol; 2016 Jul; 35(4):294-311. PubMed ID: 27119985
[TBL] [Abstract][Full Text] [Related]
13. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells.
Fischer L; Penack O; Gentilini C; Nogai A; Muessig A; Thiel E; Uharek L
Exp Hematol; 2006 Jun; 34(6):753-9. PubMed ID: 16728280
[TBL] [Abstract][Full Text] [Related]
14. KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells.
Nakadate Y; Kodera Y; Kitamura Y; Shirasawa S; Tachibana T; Tamura T; Koizumi F
Int J Cancer; 2014 May; 134(9):2146-55. PubMed ID: 24136682
[TBL] [Abstract][Full Text] [Related]
15. Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets via ARF6/PLD-1.
Ernst D; Williams BA; Wang XH; Yoon N; Kim KP; Chiu J; Luo ZJ; Hermans KG; Krueger J; Keating A
Blood Cancer J; 2019 Jan; 9(2):6. PubMed ID: 30647406
[TBL] [Abstract][Full Text] [Related]
16. Quantitating ADCC against adherent cells: Impedance-based detection is superior to release, membrane permeability, or caspase activation assays in resolving antibody dose response.
Tóth G; Szöllősi J; Vereb G
Cytometry A; 2017 Oct; 91(10):1021-1029. PubMed ID: 28945315
[TBL] [Abstract][Full Text] [Related]
17. Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells.
Wang W; Nishioka Y; Ozaki S; Jalili A; Verma VK; Hanibuchi M; Abe S; Minakuchi K; Matsumoto T; Sone S
Lung Cancer; 2009 Jan; 63(1):23-31. PubMed ID: 18524412
[TBL] [Abstract][Full Text] [Related]
18. Neutralizing Antibody Assay Development with High Drug and Target Tolerance to Support Clinical Development of an Anti-TFPI Therapeutic Monoclonal Antibody.
Xiang Y; Parng C; Olson K; Seletskaia E; Gorovits B; Jani D; Caiazzo T; Joyce A; Donley J
AAPS J; 2019 Mar; 21(3):46. PubMed ID: 30927117
[TBL] [Abstract][Full Text] [Related]
19. Development of a kinetic antibody-dependent cellular cytotoxicity assay.
Kamen L; Thakurta T; Myneni S; Zheng K; Chung S
J Immunol Methods; 2019 May; 468():49-54. PubMed ID: 30790564
[TBL] [Abstract][Full Text] [Related]
20. Development of an ELISA based bridging assay as a surrogate measure of ADCC.
Miller AS; Tejada ML; Gazzano-Santoro H
J Immunol Methods; 2012 Nov; 385(1-2):45-50. PubMed ID: 22914441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
